The efficacy of tranexamic acid in reducing blood loss in total shoulder arthroplasty : A meta-analysis
BACKGROUND: The purpose of this meta-analysis is to compare the efficacy of tranexamic acid (TXA) versus placebo after a total shoulder arthroplasty (TSA).
METHODS: In April 2017, a systematic computer-based search was conducted in the databases of PubMed, Embase, Web of Science, Cochrane Library, and Google. Studies comparing TXA versus placebo in reducing blood loss after TSA were included. The endpoints were the need for transfusion, blood loss in drainage, hemoglobin drop, and total blood loss. Stata 12.0 software was used for the meta-analysis.
RESULTS: Six studies involving a total of 637 patients met the inclusion criteria. The meta-analysis revealed that, compared with control groups, treatment with TXA could decrease the need for transfusion (P < .00001), blood loss in drainage (P = .000), hemoglobin drop (P = .001), and total blood loss (P = .000).
CONCLUSION: TXA can decrease the need for transfusion as well as total blood loss in TSA patients. There was a negative correlation between the TXA dose and the need for transfusion and blood loss in drainage. Because the administration route and the dose of TXA were different, more studies are needed in order to identify the optimal dose and route.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Medicine - 96(2017), 37 vom: 08. Sept., Seite e7880 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
He, Jing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6T84R30KC1 |
|---|
| Anmerkungen: |
Date Completed 02.10.2017 Date Revised 09.01.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000007880 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM275771180 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275771180 | ||
| 003 | DE-627 | ||
| 005 | 20231225010437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000007880 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0919.xml |
| 035 | |a (DE-627)NLM275771180 | ||
| 035 | |a (NLM)28906369 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a He, Jing |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The efficacy of tranexamic acid in reducing blood loss in total shoulder arthroplasty |b A meta-analysis |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2017 | ||
| 500 | |a Date Revised 09.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The purpose of this meta-analysis is to compare the efficacy of tranexamic acid (TXA) versus placebo after a total shoulder arthroplasty (TSA) | ||
| 520 | |a METHODS: In April 2017, a systematic computer-based search was conducted in the databases of PubMed, Embase, Web of Science, Cochrane Library, and Google. Studies comparing TXA versus placebo in reducing blood loss after TSA were included. The endpoints were the need for transfusion, blood loss in drainage, hemoglobin drop, and total blood loss. Stata 12.0 software was used for the meta-analysis | ||
| 520 | |a RESULTS: Six studies involving a total of 637 patients met the inclusion criteria. The meta-analysis revealed that, compared with control groups, treatment with TXA could decrease the need for transfusion (P < .00001), blood loss in drainage (P = .000), hemoglobin drop (P = .001), and total blood loss (P = .000) | ||
| 520 | |a CONCLUSION: TXA can decrease the need for transfusion as well as total blood loss in TSA patients. There was a negative correlation between the TXA dose and the need for transfusion and blood loss in drainage. Because the administration route and the dose of TXA were different, more studies are needed in order to identify the optimal dose and route | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 7 | |a Antifibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Tranexamic Acid |2 NLM | |
| 650 | 7 | |a 6T84R30KC1 |2 NLM | |
| 700 | 1 | |a Wang, Xi-E |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Guo-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lian-Hai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 96(2017), 37 vom: 08. Sept., Seite e7880 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2017 |g number:37 |g day:08 |g month:09 |g pages:e7880 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000007880 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2017 |e 37 |b 08 |c 09 |h e7880 | ||